New Delhi: Russia's Sputnik V, the first registered vaccine against the covid-19 infection, has an efficacy rate of 95 per cent, the developers said after the results of second interim analysis.
Sputnik V, developed by Gamaleya Institute and RDIF(Russian Direct Investment Fund), will be twice as cheap as those by US' Moderna and Pfizer who have reported similar efficacy rate.
The two dose vaccine will be available for public use for less than $10 per dose and would not require extreme cold storage for distribution.
According to a statement released by the state-run Gamaleya research centre and the Russian Direct Investment Fund (RDIF), second interim analysis of clinical trial data showed a 91.4% efficacy for the Sputnik V vaccine on day 28 after the first dose while the vaccine efficacy is over 95% 42 days after the first dose.
More than 22,000 volunteers were vaccinated with the first dose while 19,000 volunteers were given first and second doses. The results were proven effective with unexpected adverse events during the trials, it said.
Currently, 40,000 volunteers are taking part in the Phase III double-blind, randomized, placebo-controlled clinical post-registration study of the vaccine in Russia, the statement added.
“Gamaleya Center has developed one of the most efficient vaccines against coronavirus in the world with an efficacy rate of more than 90 per cent and a price that is two times lower than that of other vaccines with similar efficacy rate,” Kirill Dmitriev, CEO of the Russian Direct Investment Fund (RDIF) said in a statement.
In India, Sputnik V is yet to undergo final stage trials. Hyderabad based drug maker, Dr Reddy's has joined forces with RDIF to develop latter's vaccine candidate in the country. As part of the deal, RDIF is expected to supply 100 million doses of the vaccine to Dr Reddy's.
The first international deliveries of the Russian vaccine will be made to customers in January 2021, depending on the existing partnership between RDIF and foreign manufacturers.
The vaccination process with Sputnik V will be free of cost for Russian Citizens.
Sputnik V became world's first registered vaccine against covid-19 after it was approved by Russian Health Authorities on August 11.